PGN-EDODM1 for DM1 - PepGen's EDO platform aims to deliver higher levels of oligonucleotide to the nuclei, potentially improving the lives of people with severe neuromuscular and neurological diseases[3] - The FREEDOM-DM1 (Phase 1) trial observed a favorable emerging safety profile and a mean splicing correction of 29% after a single dose of 10 mg/kg at 28 days post-dosing[22] - Preclinical studies showed that multiple doses of PGN-EDODM1 led to greater improvement in splicing correction and myotonia compared to a single dose[35] - In DM1 patient cells, PGN-EDODM1 treatment resulted in a 54% reduction in toxic foci and a 69% correction of mis-splicing[33] - The FREEDOM trial showed a dose-dependent increase in drug tissue concentration, with approximately 12% splicing correction at 5 mg/kg and approximately 29% splicing correction at 10 mg/kg[56] PGN-EDO51 for DMD - The company is voluntarily discontinuing development of PGN-EDO51 for DMD due to the CONNECT1-EDO51 Phase 2 study results not achieving target dystrophin levels[63] - In the CONNECT1-EDO51 trial, a mean maximal exon skipping of 426% (mean increase of 35%) and a mean maximal dystrophin of 059% (mean increase of 036%) were observed after four doses of 10 mg/kg[63] EDO Platform Technology - PepGen's EDO platform is designed to solve the problem of inefficient penetration of muscle cells and the nucleus by naked oligonucleotides[13] - PepGen's EDO platform can result in up to 25X higher nuclear uptake of oligonucleotide[16] - EDO technology has been shown to increase cellular uptake and endosomal escape up to 24-fold[18]